Celularity Announces Research Collaboration with Regeneron

Celularity Inc., a biotechnology company producing allogeneic cell therapies and biomaterial products, announced a multi-year research collaboration services agreement with Regeneron Pharmaceuticals on Aug. 29, 2023 to further support the research of Regeneron’s allogeneic cell therapy candidates.

Celularity is a leader in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, like mesenchymal-like adherent stromal cells (MLASCs) and genetically modified and unmodified natural killer (NK) cells, according to the press release.

The agreement focuses on the research of a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, owned by Regeneron, designed to enhance proliferation and potency against solid tumors, according to the press release. Further, this research will be conducted at Celularity’s facility in Florham Park, NJ, with financial terms not disclosed at this time.

“The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. We believe that this relationship paves the way for future industry collaborations leveraging our world class cell therapy facilities and capabilities,” said Robert J. Hariri, MD, PhD, Celularity’s CEO, Chairman and Founder, in a press release. “We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”

Source: GlobeNewswire